Prevalence and characteristics of post-acute sequelae of SARS-CoV-2 (PASC) in non-hospitalized persons with COVID-19 enrolled in a clinical trial of early treatment (ACTIV-2)

Objectives/aim: Many persons with SARS-CoV-2 experience clinical symptoms beyond acute infection, often termed 'long COVID' or 'post-acute sequelae of SARS-CoV-2 infection (PASC)'. PASC studies embedded within COVID-19 therapeutics trials provide a unique opportunity to describe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antiviral therapy 2021-12, Vol.26, p.1
Hauptverfasser:	Evering, T H, Sanusi, B, Jilg, N, Yeh, E, Moser, C, Ritz, J, Wohl, D, Daar, E S, Klekotka, P, Javan, A C, Eron, J J, Currier, J, Hughes, M, Smith, D, Chew, K W
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents Clinical trials Cognitive ability Complications Coronaviruses COVID-19 Enrollments Infections Monoclonal antibodies Olfaction Placebos Severe acute respiratory syndrome coronavirus 2 Sleep disorders
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!